Myeloproliferative neoplasms 5 years after discovery of JAK2V617F

What is the impact of JAK2 inhibitor therapy?

Raoul Tibes, Ruben Mesa

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The watershed discovery of the JAK2V617F mutation in 2005, and the high prevalence of this mutation in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has led to a renaissance in the science and therapy of these disorders. Inhibitors of JAK2 entered clinical trials in 2007 and ushered in an unprecedented era of trials with agents specifically designed for MPNs. Currently 10 different JAK2 inhibitors have been tested in myelofibrosis (MF) with varying degrees of specificity for the JAK2 kinase. In MF these agents have shown near universal ability to decrease pathologic splenomegaly and improve disease-associated symptoms. However, the ability of these agents to significantly impact disease-associated cytopenias, JAK2 allele burden, or bone marrow histologic features remains unclear. JAK2 inhibition in polycythemia vera (PV) and essential thrombocythemia (ET) for this class of agents appears promising to reduce myeloproliferations, symptoms, and perhaps prevent thrombohemorrhagic events. Alternative agents (with alternative targets), used either alone or in combination, might perhaps further augment the spectrum of efficacy and therapeutic options for MPNs.

Original languageEnglish (US)
Pages (from-to)1178-1187
Number of pages10
JournalLeukemia and Lymphoma
Volume52
Issue number7
DOIs
StatePublished - Jul 1 2011
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Essential Thrombocythemia
Philadelphia Chromosome
Neoplasms
Polycythemia Vera
Mutation
Splenomegaly
Phosphotransferases
Therapeutics
Bone Marrow
Alleles
Clinical Trials
Renaissance

Keywords

  • JAK2
  • myeloproliferative disorders
  • novel therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F : What is the impact of JAK2 inhibitor therapy? / Tibes, Raoul; Mesa, Ruben.

In: Leukemia and Lymphoma, Vol. 52, No. 7, 01.07.2011, p. 1178-1187.

Research output: Contribution to journalReview article

@article{f8180ff3e64f415a87b7be7b856a7993,
title = "Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: What is the impact of JAK2 inhibitor therapy?",
abstract = "The watershed discovery of the JAK2V617F mutation in 2005, and the high prevalence of this mutation in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has led to a renaissance in the science and therapy of these disorders. Inhibitors of JAK2 entered clinical trials in 2007 and ushered in an unprecedented era of trials with agents specifically designed for MPNs. Currently 10 different JAK2 inhibitors have been tested in myelofibrosis (MF) with varying degrees of specificity for the JAK2 kinase. In MF these agents have shown near universal ability to decrease pathologic splenomegaly and improve disease-associated symptoms. However, the ability of these agents to significantly impact disease-associated cytopenias, JAK2 allele burden, or bone marrow histologic features remains unclear. JAK2 inhibition in polycythemia vera (PV) and essential thrombocythemia (ET) for this class of agents appears promising to reduce myeloproliferations, symptoms, and perhaps prevent thrombohemorrhagic events. Alternative agents (with alternative targets), used either alone or in combination, might perhaps further augment the spectrum of efficacy and therapeutic options for MPNs.",
keywords = "JAK2, myeloproliferative disorders, novel therapy",
author = "Raoul Tibes and Ruben Mesa",
year = "2011",
month = "7",
day = "1",
doi = "10.3109/10428194.2011.566952",
language = "English (US)",
volume = "52",
pages = "1178--1187",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Myeloproliferative neoplasms 5 years after discovery of JAK2V617F

T2 - What is the impact of JAK2 inhibitor therapy?

AU - Tibes, Raoul

AU - Mesa, Ruben

PY - 2011/7/1

Y1 - 2011/7/1

N2 - The watershed discovery of the JAK2V617F mutation in 2005, and the high prevalence of this mutation in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has led to a renaissance in the science and therapy of these disorders. Inhibitors of JAK2 entered clinical trials in 2007 and ushered in an unprecedented era of trials with agents specifically designed for MPNs. Currently 10 different JAK2 inhibitors have been tested in myelofibrosis (MF) with varying degrees of specificity for the JAK2 kinase. In MF these agents have shown near universal ability to decrease pathologic splenomegaly and improve disease-associated symptoms. However, the ability of these agents to significantly impact disease-associated cytopenias, JAK2 allele burden, or bone marrow histologic features remains unclear. JAK2 inhibition in polycythemia vera (PV) and essential thrombocythemia (ET) for this class of agents appears promising to reduce myeloproliferations, symptoms, and perhaps prevent thrombohemorrhagic events. Alternative agents (with alternative targets), used either alone or in combination, might perhaps further augment the spectrum of efficacy and therapeutic options for MPNs.

AB - The watershed discovery of the JAK2V617F mutation in 2005, and the high prevalence of this mutation in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has led to a renaissance in the science and therapy of these disorders. Inhibitors of JAK2 entered clinical trials in 2007 and ushered in an unprecedented era of trials with agents specifically designed for MPNs. Currently 10 different JAK2 inhibitors have been tested in myelofibrosis (MF) with varying degrees of specificity for the JAK2 kinase. In MF these agents have shown near universal ability to decrease pathologic splenomegaly and improve disease-associated symptoms. However, the ability of these agents to significantly impact disease-associated cytopenias, JAK2 allele burden, or bone marrow histologic features remains unclear. JAK2 inhibition in polycythemia vera (PV) and essential thrombocythemia (ET) for this class of agents appears promising to reduce myeloproliferations, symptoms, and perhaps prevent thrombohemorrhagic events. Alternative agents (with alternative targets), used either alone or in combination, might perhaps further augment the spectrum of efficacy and therapeutic options for MPNs.

KW - JAK2

KW - myeloproliferative disorders

KW - novel therapy

UR - http://www.scopus.com/inward/record.url?scp=79959591958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959591958&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.566952

DO - 10.3109/10428194.2011.566952

M3 - Review article

VL - 52

SP - 1178

EP - 1187

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -